<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cervical cancer TNM staging AJCC UICC 9th edition</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cervical cancer TNM staging AJCC UICC 9th edition</h1>
<div class="graphic"><div class="figure"><div class="ttl">Cervical cancer TNM staging AJCC UICC 9th edition</div><div class="cntnt"><table cellspacing="0"><colgroup span="4" width="25%"></colgroup> <tbody> <tr class="divider_bottom"> <td colspan="4">The definitions of the T categories correspond to the stages accepted by the Fédération Internationale de Gynécologie et d'Obstétrique (FIGO). Both systems are included for comparison.</td> </tr> <tr> <td class="subtitle1_left" colspan="4">Primary tumor (T)*</td> </tr> <tr class="divider_bottom"> <td><strong>T category</strong></td> <td><strong>FIGO stage</strong></td> <td colspan="2"><strong>T criteria</strong></td> </tr> <tr> <td class="indent1">TX</td> <td> </td> <td colspan="2">Primary tumor cannot be assessed</td> </tr> <tr> <td class="indent1">T0</td> <td> </td> <td colspan="2">No evidence of primary tumor</td> </tr> <tr> <td class="indent1">T1</td> <td>I</td> <td colspan="2">Carcinoma is strictly confined to the cervix (extension to the corpus should be disregarded)</td> </tr> <tr> <td class="indent2">T1a</td> <td>IA</td> <td colspan="2">Invasive carcinoma that can be diagnosed only by microscopy with maximum depth of invasion ≤5 mm</td> </tr> <tr> <td class="indent3">T1a1</td> <td>IA1</td> <td colspan="2">Measured stromal invasion ≤3 mm in depth</td> </tr> <tr> <td class="indent3">T1a2</td> <td>IA2</td> <td colspan="2">Measured stromal invasion &gt;3 mm and ≤5 mm in depth</td> </tr> <tr> <td class="indent2">T1b</td> <td>IB</td> <td colspan="2"> <p>Invasive carcinoma with measured deepest invasion &gt;5 mm (greater than stage IA); lesion limited to the cervix uteri with size measured by maximum tumor diameter.</p> <em>NOTE:</em> The involvement of vascular/lymphatic spaces should not change the staging. The lateral extent of the lesion is no longer considered.</td> </tr> <tr> <td class="indent3">T1b1</td> <td>IB1</td> <td colspan="2">Invasive carcinoma &gt;5 mm depth of stromal invasion and ≤2 cm in greatest dimension</td> </tr> <tr> <td class="indent3">T1b2</td> <td>IB2</td> <td colspan="2">Invasive carcinoma &gt;2 cm and ≤4 cm in greatest dimension</td> </tr> <tr> <td class="indent3">T1b3</td> <td>IB3</td> <td colspan="2">Invasive carcinoma &gt;4 cm in greatest dimension</td> </tr> <tr> <td class="indent1">T2</td> <td>II</td> <td colspan="2">Carcinoma invades beyond the uterus, but has not extended onto the lower third of the vagina or to the pelvic wall</td> </tr> <tr> <td class="indent2">T2a</td> <td>IIA</td> <td colspan="2">Involvement limited to the upper two-thirds of the vagina without parametrial invasion</td> </tr> <tr> <td class="indent3">T2a1</td> <td>IIA1</td> <td colspan="2">Invasive carcinoma ≤4 cm in greatest dimension</td> </tr> <tr> <td class="indent3">T2a2</td> <td>IIA2</td> <td colspan="2">Invasive carcinoma &gt;4 cm in greatest dimension</td> </tr> <tr> <td class="indent2">T2b</td> <td>IIB</td> <td colspan="2">With parametrial invasion but not up to the pelvic wall</td> </tr> <tr> <td class="indent1">T3</td> <td>III</td> <td colspan="2"> <p>Carcinoma involves the lower third of the vagina and/or extends to the pelvic wall and/or causes hydronephrosis or nonfunctioning kidney.</p> <em>NOTE:</em> The pelvic wall is defined as the muscle, fascia, neurovascular structures, and skeletal portions of the bony pelvis. Cases with no cancer-free space between the tumor and pelvic wall by rectal examination are FIGO III.</td> </tr> <tr> <td class="indent2">T3a</td> <td>IIIA</td> <td colspan="2">Carcinoma involves lower third of the vagina, with no extension to the pelvic wall</td> </tr> <tr> <td class="indent2">T3b</td> <td>IIIB</td> <td colspan="2">Extension to the pelvic wall and/or hydronephrosis or nonfunctioning kidney (unless known to be due to another cause)</td> </tr> <tr> <td class="indent1">T4</td> <td>IVA</td> <td colspan="2">Carcinoma has involved (biopsy-proven) the mucosa of the bladder or rectum, or has spread to adjacent organs. (Bullous edema, as such, does not permit a case to be assigned to stage IVA.)</td> </tr> <tr class="border_bottom_thick"> <td class="indent1" colspan="4"><strong>Primary tumor suffix</strong> <ul class="none"> <li>(m) Multiple synchronous primary tumors</li> </ul> </td> </tr> <tr class="divider_bottom"> <td colspan="4">The definitions of the N categories correspond to the stages accepted by the Fédération Internationale de Gynécologie et d'Obstétrique (FIGO). Both systems are included for comparison.</td> </tr> <tr> <td class="subtitle1_left" colspan="4">Regional lymph nodes (N)*</td> </tr> <tr class="divider_bottom"> <td><strong>N category</strong></td> <td><strong>FIGO stage</strong></td> <td colspan="2"><strong>N criteria</strong></td> </tr> <tr> <td class="indent1">NX</td> <td> </td> <td colspan="2">Regional lymph nodes cannot be assessed</td> </tr> <tr> <td class="indent1">N0</td> <td> </td> <td colspan="2">No regional lymph node metastasis</td> </tr> <tr> <td class="indent2">N0(i+)</td> <td> </td> <td colspan="2">Isolated tumor cells in regional lymph node(s) ≤0.2 mm, or single cells or clusters of cells ≤200 cells in a single lymph node cross section</td> </tr> <tr> <td class="indent1">N1</td> <td>IIIC1</td> <td colspan="2">Regional lymph node metastasis to pelvic lymph nodes only</td> </tr> <tr> <td class="indent2">N1mi</td> <td>IIIC1</td> <td colspan="2">Regional lymph node metastasis (&gt;0.2 mm but ≤2.0 mm in diameter) to pelvic lymph nodes</td> </tr> <tr> <td class="indent2">N1a</td> <td>IIIC1</td> <td colspan="2">Regional lymph node metastasis (&gt;2.0 mm in diameter) to pelvic lymph nodes</td> </tr> <tr> <td class="indent1">N2</td> <td>IIIC2</td> <td colspan="2">Regional lymph node metastasis to para-aortic lymph nodes, with or without positive pelvic lymph nodes</td> </tr> <tr> <td class="indent2">N2mi</td> <td>IIIC2</td> <td colspan="2">Regional lymph node metastasis (&gt;0.2 mm but ≤2.0 mm in diameter) to para-aortic lymph nodes, with or without positive pelvic lymph nodes</td> </tr> <tr> <td class="indent2">N2a</td> <td>IIIC2</td> <td colspan="2">Regional lymph node metastasis (&gt;2.0 mm in diameter) to para-aortic lymph nodes, with or without positive pelvic lymph nodes</td> </tr> <tr> <td class="indent1" colspan="4"><em>NOTE:</em> Suffix (f) is added to the N category when metastasis is identified only by FNA or core biopsy. Suffix (sn) is added to the N category when metastasis is identified only by sentinel lymph node biopsy.</td> </tr> <tr class="border_bottom_thick"> <td class="indent1" colspan="4"><strong>Regional lymph nodes suffix</strong> <ul class="none"> <li>(f) FNA or core biopsy</li> <li>(sn) Sentinel node procedure</li> </ul> </td> </tr> <tr class="divider_bottom"> <td colspan="4">The definitions of the M categories correspond to the stages accepted by the Fédération Internationale de Gynécologie et d'Obstétrique (FIGO). Both systems are included for comparison.</td> </tr> <tr> <td class="subtitle1_left" colspan="4">Distant metastasis (M)*</td> </tr> <tr class="divider_bottom"> <td><strong>M category</strong></td> <td><strong>FIGO stage</strong></td> <td colspan="2"><strong>M criteria</strong></td> </tr> <tr> <td class="indent1">M0</td> <td> </td> <td colspan="2">No distant metastasis</td> </tr> <tr> <td class="indent1">cM1</td> <td>IVB</td> <td colspan="2">Distant metastasis (includes metastasis to inguinal lymph nodes, intraperitoneal disease, lung, liver, or bone) (excludes metastasis to pelvic or para-aortic lymph nodes, or vagina)</td> </tr> <tr class="border_bottom_thick"> <td class="indent1">pM1</td> <td>IVB</td> <td colspan="2">Microscopic confirmation of distant metastasis (includes metastasis to inguinal lymph nodes, intraperitoneal disease, lung, liver, or bone) (excludes metastasis to pelvic or paraaortic lymph nodes, or vagina)</td> </tr> <tr class="divider_bottom"> <td colspan="4">AJCC prognostic stage group is assigned based on the stage classification and categories chosen.*</td> </tr> <tr> <td class="subtitle1_left" colspan="4">Prognostic stage groups</td> </tr> <tr class="divider_bottom"> <td><strong>When T is...</strong></td> <td><strong>And N is...</strong></td> <td><strong>And M is...</strong></td> <td><strong>Then the stage group is...</strong></td> </tr> <tr> <td class="indent1">T1</td> <td>N0</td> <td>M0</td> <td>I</td> </tr> <tr> <td class="indent1">T1a</td> <td>N0</td> <td>M0</td> <td>IA</td> </tr> <tr> <td class="indent1">T1a1</td> <td>N0</td> <td>M0</td> <td>IA1</td> </tr> <tr> <td class="indent1">T1a2</td> <td>N0</td> <td>M0</td> <td>IA2</td> </tr> <tr> <td class="indent1">T1b</td> <td>N0</td> <td>M0</td> <td>IB</td> </tr> <tr> <td class="indent1">T1b1</td> <td>N0</td> <td>M0</td> <td>IB1</td> </tr> <tr> <td class="indent1">T1b2</td> <td>N0</td> <td>M0</td> <td>IB2</td> </tr> <tr> <td class="indent1">T1b3</td> <td>N0</td> <td>M0</td> <td>IB3</td> </tr> <tr> <td class="indent1">T2</td> <td>N0</td> <td>M0</td> <td>II</td> </tr> <tr> <td class="indent1">T2a</td> <td>N0</td> <td>M0</td> <td>IIA</td> </tr> <tr> <td class="indent1">T2a1</td> <td>N0</td> <td>M0</td> <td>IIA1</td> </tr> <tr> <td class="indent1">T2a2</td> <td>N0</td> <td>M0</td> <td>IIA2</td> </tr> <tr> <td class="indent1">T2b</td> <td>N0</td> <td>M0</td> <td>IIB</td> </tr> <tr> <td class="indent1">T3</td> <td>N0</td> <td>M0</td> <td>III</td> </tr> <tr> <td class="indent1">T3a</td> <td>N0</td> <td>M0</td> <td>IIIA</td> </tr> <tr> <td class="indent1">T3b</td> <td>N0</td> <td>M0</td> <td>IIIB</td> </tr> <tr> <td class="indent1">TX, T0, T1-3</td> <td>N1</td> <td>M0</td> <td>IIIC1</td> </tr> <tr> <td class="indent1">TX, T0, T1-3</td> <td>N2</td> <td>M0</td> <td>IIIC2</td> </tr> <tr> <td class="indent1">T4</td> <td>Any N</td> <td>M0</td> <td>IVA</td> </tr> <tr> <td class="indent1">Any T</td> <td>Any N</td> <td>M1</td> <td>IVB</td> </tr> </tbody></table></div><div class="graphic_footnotes"><p>TNM: tumor, node, metastasis; AJCC: American Joint Committee on Cancer; UICC: International Union Against Cancer.</p>
* AJCC data elements required for staging are identified with an asterisk.</div><div class="graphic_reference">Used with permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original and primary source for this information is the AJCC Cancer Staging System: Cervix Uteri, Version 9 (2020), published by the American College of Surgeons (ACS).</div><div id="graphicVersion">Graphic 139268 Version 2.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
